Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation

Journal of Cystic Fibrosis

Volumn 15, Issue 6, 2016, Pages e67-e69

  Sermet Gaudelus, Isabelle ^a   Delion, Martial ^b   Durieu, Isabelle ^c   Jacquot, Jacky ^b   Hubert, Dominique ^d  

^a INSTITUT NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^c UNIVERSITÉ LYON 1   (France)

^d université Paris Cité   (France)

Author keywords

Bone density; CFTR corrector; Cystic fibrosis; RANKL

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR; AMINOPHENOL DERIVATIVE; CHLORIDE CHANNEL STIMULATING AGENT; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; BONE CELL; BONE DEMINERALIZATION; BONE DENSITY; BONE MINERALIZATION; BONE REMODELING; CELL FUNCTION; CLINICAL ARTICLE; CYSTIC FIBROSIS; DISEASE SEVERITY; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENE MUTATION; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOLYSIS; CELL CULTURE; COMPLICATION; DRUG EFFECTS; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MUTATION; PHYSIOLOGY; STATISTICS;

ADULT; AMINOPHENOLS; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; CELLS, CULTURED; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; OSTEOBLASTS; QUINOLONES; STATISTICS AS TOPIC;

EID: 84998577672     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.09.003     Document Type: Article

References (13)

1. [1] Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.
2. [2] Accurso, F.J., Rowe, S.M., Clancy, J.P., Boyle, M.P., Dunitz, J.M., Durie, P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363 (2010), 1991–2003.
3. [3] Sermet-Gaudelus, I., Bianchi, M.L., Garabédian, M., Aris, R.M., Morton, A., Hardin, D.S., et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 10:Suppl. 2 (2011), S16–S23.
4. [4] Le Henaff, C., Mansouri, R., Modrowski, D., Zarka, M., Geoffroy, V., Marty, C., et al. Increased NF-kappaB activity and decreased Wnt/beta-catenin signaling mediate reduced osteoblast differentiation and function in DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) mice. J Biol Chem 290 (2015), 18009–18017.
5. [5] Jacquot, J., Delion, M., Gangloff, S., Braux, J., Velard, F., Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. Osteoporos Int 27 (2016), 1401–1412.
6. [6] Le Heron, L., Guillaume, C., Velard, F., Braux, J., Touqui, L., Moriceau, S., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E(2) in human bone. J Cyst Fibros 9 (2010), 69–72.
7. [7] Baron, R., Kneissel, M., WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19 (2013), 179–192.
8. [8] Shead, E.F., Haworth, C.S., Barker, H., Bilton, D., Compston, J.E., Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros 9 (2010), 93–98.
9. [9] Ambroszkiewicz, J., Sands, D., Gajewska, J., Chelchowska, M., Laskowska-Klita, T., Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis. Adv Med Sci 58 (2013), 338–343.
10. [10] Shmarina, G., Pukhalsky, A., Petrova, N., Zakharova, E., Avakian, L., Kapranov, N., et al. TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression. J Transl Med, 11, 2013, 19.
11. [11] Velard, F., Delion, M., Lemaire, F., Tabary, O., Guillaume, C., Le Pimpec, B.F., et al. Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?. Eur Respir J 45 (2015), 845–848.
12. [12] Velard, F., Delion, M., Le Henaff, C., Guillaume, C., Gangloff, S., Jacquot, J., et al. Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator. Am J Respir Crit Care Med 189 (2014), 746–748.
13. [13] Le Henaff, C., Hay, E., Velard, F., Marty, C., Tabary, O., Marie, P.J., et al. Enhanced F508del-CFTR channel activity ameliorates bone pathology in murine cystic fibrosis. Am J Pathol 184 (2014), 1132–1141.